Back to Search
STUART SUGARMAN, MD
Specialist
NPI: 1407926835Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
5801A(WY)
Research & Publications (16)
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
PMID 18751888·Breast Cancer Res Treat·2009
3-trial
Prevalence of high-risk human papillomavirus in an inner-city population with atypical squamous cells of undetermined significance.
PMID 19387124·J Low Genit Tract Dis·2009
8-other
No more business as usual: enticing companies to sharply lower the public health costs of the products they sell.
PMID 19286061·Public Health·2009
8-other
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Should we use regulation to demand improved public health outcomes from industry? Yes.
PMID 18832416·BMJ·2008
8-other
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
PMID 18952555·Clin Breast Cancer·2008
3-trial
Using performance-based regulation to reduce childhood obesity.
PMID 19017402·Aust New Zealand Health Policy·2008
8-other
Cases in vaccine court--legal battles over vaccines and autism.
PMID 17898095·N Engl J Med·2007
8-other
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
PMID 18065731·J Clin Oncol·2007
2-rct
Fighting childhood obesity through performance-based regulation of the food industry.
PMID 17679177·Duke Law J·2007
8-other
Case files of the University of Massachusetts fellowship in medical toxicology: three patients with an industrial radiography source exposure.
PMID 18072138·J Med Toxicol·2006
5-case
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
PMID 10910945·Carcinogenesis·2000
8-other
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
PMID 11032598·J Clin Oncol·2000
3-trial
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
PMID 10829049·J Clin Oncol·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 555 E BROADWAY, SUITE 220
JACKSON, WY 83001 - Phone
- (307) 734-8800
Quick Facts
- NPI
- 1407926835
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 16
Are you this provider?
Claim Your Profile